New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLiraglutide vs AHK-Cu

Liraglutide vs AHK-Cu

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide
Skin & CosmeticAnti-Aging & Longevity
AHK-Cu
Summary
Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
Half-Life
~13 hours (once-daily dosing)
Hours (topical, variable by formulation)
Admin Route
SubQ
Topical, Scalp application, Subcutaneous (research)
Research
Typical Dose
Start 0.6 mg, titrate to 3 mg
0.01–0.1% concentration
Frequency
Once daily
Once or twice daily
Key Benefits
  • Promotes weight loss (5–10% average)
  • Reduces appetite and caloric intake
  • Improves blood glucose control (HbA1c reduction)
  • Reduces cardiovascular events in T2DM (LEADER trial)
  • Slows gastric emptying
  • FDA-approved for T2DM and chronic weight management
  • Cardioprotective effects shown in clinical trials
  • May improve fatty liver (NAFLD/NASH)
  • Stimulates hair follicle growth and reduces shedding
  • Increases dermal papilla cell proliferation
  • Promotes wound healing and skin regeneration
  • Antioxidant protection via superoxide dismutase activation
  • Improves skin elasticity and firmness
  • Supports collagen and elastin production
Side Effects
  • Nausea (very common, especially initially)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • +5 more
  • Generally well-tolerated topically
  • Mild scalp irritation or redness in sensitive individuals
  • Possible temporary hair shedding phase at treatment initiation
  • Copper accumulation with excessive systemic use (rare)
Stacks With